English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Early diagnostic marker panel determination for microarray based clinical studies

Jaeger, J., Weichenhan, D., Ivandic, B., & Spang, R. (2005). Early diagnostic marker panel determination for microarray based clinical studies. Statistical Applications in Genetics and Molecular Biology, 4(1), Article 9-Article 9.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/11858/00-001M-0000-0010-8673-E Version Permalink: http://hdl.handle.net/11858/00-001M-0000-0010-8674-C
Genre: Journal Article
Alternative Title : Online-Ressource

Files

show Files
hide Files
:
viewcontent.pdf (Any fulltext), 288KB
Name:
viewcontent.pdf
Description:
-
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
eDoc_access: PUBLIC
License:
-

Locators

show

Creators

show
hide
 Creators:
Jaeger, Jochen1, Author
Weichenhan, Dieter, Author
Ivandic, Boris, Author
Spang, Rainer2, Author              
Affiliations:
1Max Planck Society, ou_persistent13              
2Dept. of Computational Molecular Biology (Head: Martin Vingron), Max Planck Institute for Molecular Genetics, Max Planck Society, ou_1433547              

Content

show
hide
Free keywords: -
 Abstract: We present a novel, cost efficient two-phase design for predictive clinical gene expression studies: early marker panel determination (EMPD). In Phase-1, genome-wide microarrays are used only for a small number of individual patient samples. From this Phase-1 data a panel of marker genes is derived. In Phase-2, the expression values of these marker panel genes are measured for a large group of patients and a predictive classification model is learned from this data. Phase-2 does not require the use of expensive whole genome microarrays, thus making EMPD a cost efficient alternative for current trials. The expected performance loss of EMPD is compared to designs which use genome-wide microarrays for all patients. We also examine the trade-off between the number of patients included in Phase-1 and the number of marker genes required in Phase-2. By analysis of five published datasets we find that in Phase-1 already 16 patients per group are sufficient to determine a suitable marker panel of 10 genes, and that this early decision compromises the final performance only marginally.

Details

show
hide
Language(s): eng - English
 Dates: 2005-04-26
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: eDoc: 265102
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Statistical Applications in Genetics and Molecular Biology
  Alternative Title : Online-Ressource
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 4 (1) Sequence Number: - Start / End Page: Article 9 - Article 9 Identifier: ISSN: 1544-6115